Literature DB >> 12021165

Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets.

James A Fagin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12021165     DOI： 10.1210/endo.143.6.8832

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  10 in total

1.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

2.  Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark.

Authors:  Martha A Zeiger
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

Review 3.  Cytogenomics of cancers: from chromosome to sequence.

Authors:  Alain Bernheim
Journal:  Mol Oncol       Date:  2010-06-11       Impact factor: 6.603

4.  Effect of BMAP-28 on human thyroid cancer TT cells is mediated by inducing apoptosis.

Authors:  Daqi Zhang; Lanlan Wan; Jinnan Zhang; Chang Liu; Hui Sun
Journal:  Oncol Lett       Date:  2015-08-14       Impact factor: 2.967

5.  The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Authors:  Rosa Marina Melillo; Anna Maria Cirafici; Valentina De Falco; Marie Bellantoni; Gennaro Chiappetta; Alfredo Fusco; Francesca Carlomagno; Antonella Picascia; Donatella Tramontano; Giovanni Tallini; Massimo Santoro
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

6.  In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Authors:  Frauke Bentzien; Marcus Zuzow; Nathan Heald; Anna Gibson; Yongchang Shi; Leanne Goon; Peiwen Yu; Stefan Engst; Wentao Zhang; Donghui Huang; Lora Zhao; Valentina Vysotskaia; Felix Chu; Rajana Bautista; Belinda Cancilla; Peter Lamb; Alison H Joly; F Michael Yakes
Journal:  Thyroid       Date:  2013-09-17       Impact factor: 6.568

7.  IRF5 promotes the proliferation of human thyroid cancer cells.

Authors:  Michele Massimino; Paolo Vigneri; Manuela Fallica; Annamaria Fidilio; Alessandra Aloisi; Francesco Frasca; Livia Manzella
Journal:  Mol Cancer       Date:  2012-04-16       Impact factor: 27.401

8.  Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.

Authors:  Emira Ayroldi; Maria Grazia Petrillo; Maria Cristina Marchetti; Lorenza Cannarile; Simona Ronchetti; Erika Ricci; Luigi Cari; Nicola Avenia; Sonia Moretti; Efisio Puxeddu; Carlo Riccardi
Journal:  Cell Death Dis       Date:  2018-02-21       Impact factor: 8.469

9.  Identification of differentially expressed genes in papillary thyroid cancers.

Authors:  Ki-Young Lee; Song Mei Huang; Shengjin Li; Jin-Man Kim
Journal:  Yonsei Med J       Date:  2009-02-24       Impact factor: 2.759

10.  A unique RET EXON 11 (G691S) polymorphism in an Indian patient with a collision tumor of the thyroid.

Authors:  Bharat Rekhi; Rakesh R Badhe; Maria Alina Desouza; Devendra Chaukar; Anil K D'Cruz; Suprita Arya; S V Kane
Journal:  Diagn Pathol       Date:  2007-10-16       Impact factor: 2.644
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.